Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

83.52EUR
16 Feb 2018
Change (% chg)

€1.00 (+1.21%)
Prev Close
€82.52
Open
€82.90
Day's High
€84.06
Day's Low
€82.48
Volume
568,716
Avg. Vol
554,490
52-wk High
€115.20
52-wk Low
€80.92

Latest Key Developments (Source: Significant Developments)

Nestle declines to comment on interest in Pfizer, Merck units
Thursday, 15 Feb 2018 04:48am EST 

Feb 15 (Reuters) - Nestle Sa ::CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS.ZONE AMERICAS HEAD SAYS EXPECTS TO SEE LIMITED PRICE INCREASES IN THE U.S. THIS YEAR, COUNTS ON VOLUME GROWTH TO DRIVE IMPROVEMENT IN ORGANIC GROWTH.  Full Article

Pangaea Oncology Signs Contract For Genetic Analysis With German's Merck
Thursday, 15 Feb 2018 03:58am EST 

Feb 15 (Reuters) - PANGAEA ONCOLOGY SA ::SIGNS CONTRACT FOR GENETIC ANALYSIS WITH GERMAN'S MERCK KGAA FOR 0.3 MILLION EUROS.THE TERM OF THE CONTRACT IS BETWEEN 12 AND 24 MONTHS.  Full Article

Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer
Thursday, 11 Jan 2018 07:30am EST 

Jan 11 (Reuters) - Merck KGAA ::FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER.  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Tuesday, 2 Jan 2018 04:05pm EST 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

HTG Molecular Diagnostics Expands Its Collaboration With Merck
Tuesday, 26 Dec 2017 04:01pm EST 

Dec 26 (Reuters) - Htg Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS EXPANDS ITS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY.HTG MOLECULAR - TO DEVELOP CUSTOM PROFILING ASSAY TO SUPPORT BIOMARKER RESEARCH FOR 6 INDICATIONS WITHIN MERCK KGAA'S DRUG DEVELOPMENT PIPELINE.  Full Article

FDA grants second breakthrough therapy designation for Avelumab in hard-to-treat cancer​
Thursday, 21 Dec 2017 01:00pm EST 

Dec 21 (Reuters) - Merck Kgaa ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.SAYS ‍SECOND BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN HARD-TO-TREAT CANCER​.SAYS ‍RENAL CELL CARCINOMA, MOST COMMON FORM OF KIDNEY CANCER, HAS A POOR PROGNOSIS IN ADVANCED STAGE​.SAYS ‍JAVELIN RENAL CLINICAL DEVELOPMENT PROGRAM IS ONGOING, INCLUDING PHASE III FIRST-LINE STUDY​.SAYS ‍FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA(®) (AXITINIB)* FOR TREATMENT-NAÏVE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA​.  Full Article

Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta
Thursday, 21 Dec 2017 01:00pm EST 

Dec 21 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY.  Full Article

Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors
Wednesday, 20 Dec 2017 08:05am EST 

Dec 20 (Reuters) - MERCK KGAA ::MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS.  Full Article

Merck KGaA ‍Receives Approval (Updated Registration) For Cladribine Tablets In Australia​
Thursday, 7 Dec 2017 04:11am EST 

Dec 7 (Reuters) - Merck KGaA ::SAYS ‍RECEIVES APPROVAL (UPDATED REGISTRATION) FOR CLADRIBINE TABLETS IN AUSTRALIA​.  Full Article

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.